RJX + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Critical Limb Ischemia
Conditions
Critical Limb Ischemia
Trial Timeline
Aug 24, 2018 → Jan 15, 2019
NCT ID
NCT03680105About RJX + Placebo
RJX + Placebo is a phase 1 stage product being developed by ICON plc. for Critical Limb Ischemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03680105. Target conditions include Critical Limb Ischemia.
What happened to similar drugs?
4 of 9 similar drugs in Critical Limb Ischemia were approved
Approved (4) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03680105 | Phase 1 | Completed |
Competing Products
13 competing products in Critical Limb Ischemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 43 |
| Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose | Merck | Phase 1 | 29 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Amgen | Approved | 39 |
| intensive insulin therapy to maintain normoglycemia | Novo Nordisk | Phase 2 | 35 |
| Midazolam + Dexmedetomidine | Pfizer | Pre-clinical | 26 |
| Apixaban + ASA + Clopidogrel 75mg | Pfizer | Phase 3 | 36 |
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 43 |
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 40 |
| treprostinil dienthanolmine sustained release + Placebo | United Therapeutics | Phase 2 | 32 |
| Remodulin® (treprostinil sodium) Injection | United Therapeutics | Phase 3 | 29 |
| Olimel (5.7%E / N9E) | Baxter | Phase 3 | 29 |
| Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Baxter | Approved | 44 |
| Ixmyelocel-T | Vericel | Phase 3 | 34 |